ArticleCell death and differentiation2026
Ubiquitin-specific protease 48 drives malignant progression of colorectal cancer by suppressing autophagy through stabilizing sequestosome 1.
Article in Cell death and differentiation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Deubiquitinase USP48 Promotes Gastric Cancer Peritoneal Metastasis by Stabilizing S100A9 to Drive Neutrophil Extracellular Traps Formation.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Multi-omics-driven precision medicine.iMeta · 2026Review
- Autophagy Dysregulation in Crohn's Disease and Colorectal Cancer-An Analysis ofCurrent issues in molecular biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Colorectal cancer (CRC) is the third malignant tumor in incidence rate and the second leading cause of cancer death worldwide. The progression of CRC is associated with both autophagy and ubiquitin-specific proteases (USPs). While USPs have been shown to regulate autophagy, their specific involvement in CRC autophagy remains largely unexplored. Herein, through the analysis of autophagy-related protein expression levels and proteomics, we found that high expression of USP48 was closely related to the inhibition of autophagy in CRC. And further analysis of CRC tissues showed that USP48 served as an independent risk factor for CRC patient prognosis. In vitro, we observed that USP48 significantly enhanced the proliferative, migration and invasion capacities of CRC cells. In vivo experiments showed that USP48 knockdown significantly inhibited the growth of subcutaneous tumors in nude mice, and the deletion of USP48 in intestinal epithelial cells reduced the number of intestinal tumors and mortality rate of mice. Mechanistically, USP48 was found to interact with the autophagy substrate protein sequestosome 1 (SQSTM1) and induce its deubiquitination at K420. This process inhibited autophagy, consequently maintaining the protein stability of SQSTM1. Rescue experiments demonstrated that SQSTM1 was the key target for USP48 to inhibit autophagy and promote CRC progression. Based on these findings, we constructed a tetrahedral DNA nanomaterial loaded with USP48 small interfering RNA (siRNA), which could effectively inhibited the progression of CRC in vivo while exhibiting excellent biocompatibility. In summary, our findings highlighted the role of USP48 in promoting CRC progression via the stabilization of SQSTM1, which leads to the suppression of autophagy. Thus, USP48 may be a potential therapeutic target for CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.